Akums Drugs launches first stable oral suspension for Sickle Cell Disease

Major Pharma company Akums Drugs announced the launch of India’s first stable oral suspension for Sickle Cell Disease. This innovative product is thoughtfully accompanied by oral syringes for precise dosage administration, said the pharma company.

In a statement it said, “Akums Drugs and Pharmaceuticals has achieved a groundbreaking milestone: the development of the India’s first room temperature stable oral suspension of Hydroxyurea, tailored specifically for patients battling Sickle Cell Disease, spanning across all age groups. This innovative product is thoughtfully accompanied by oral syringes for precise dosage administration”.

It said that in contrast to the current import price of approximately INR 77,000 for the global brand of Hydroxyurea solution (which necessitates storage at 2-8° Celsius), Akums is passionately committed to advancing a noble cause and ensuring accessibility to affordable medication. In alignment with the objectives outlined in the National Sickle Cell Anemia Mission, Akums pledges to provide this life-changing medicine to the government at a cost of less than INR 600, thus embodying the spirit of “Make in India” and fostering widespread benefit to the masses.